Serine racemase binds to PICK1: Potential relevance to schizophrenia

Molecular Psychiatry

Volumn 11, Issue 2, 2006, Pages 150-157

  Fujii, K ^a,b   Maeda, K ^a,c   Hikida, T ^a   Mustafa, A K ^a   Balkissoon, R ^a   Xia, J ^a   Yamada, T ^c   Ozeki, Y ^a,b   Kawahara, R ^c   Okawa, M ^b   Huganir, R L ^a,b   Ujike, H ^d   Snyder, S H ^a   Sawa, A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

Case control study; D serine; PICK1; Schizophrenia; Serine racemase; Yeast two hybrid

Indexed keywords

DEXTRO SERINE; ENZYME; HYDROXYAMINO ACID; PDZ PROTEIN; PROTEIN INTERACTING WITH PROTEIN KINASE C; PROTEIN KINASE C; SERINE RACEMASE; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ARTICLE; CHROMOSOME; ENZYME BINDING; FEMALE; GENE FUNCTION; GENE LOCATION; GENETIC CODE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SCHIZOPHRENIA;

ADULT; ANIMALS; ASTROCYTES; CARRIER PROTEINS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICE; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RACEMASES AND EPIMERASES; SCHIZOPHRENIA; SERINE;

EID: 31544465933     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4001776     Document Type: Article

References (64)

1. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367-1377.
2. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-1308.
3. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002; 42: 165-179.
4. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science 2002; 296: 692-695.
5. Sawa A, Snyder SH. Schizophrenia: neural mechanisms for novel therapies. Mol Med 2003; 9: 3-9.
6. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987; 325: 529-531.
7. Schell MJ, Molliver ME, Snyder SH. D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc Natl Acad Sci USA 1995; 92: 3948-3952.
8. Schell MJ, Brady Jr RO, Molliver ME, Snyder SH. D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors. J Neurosci 1997; 17: 1604-1615.
9. Snyder SH, Ferris CD. Novel neurotransmitters and their neuropsychiatric relevance. Am J Psychiatry 2000; 157: 1738-1751.
10. Snyder SH, Kim PM. D-amino acids as putative neurotransmitters: focus on D-serine. Neurochem Res 2000; 25: 553-560.
11. Mothet JP, Parent AT, Wolosker H, Brady Jr RO, Linden DJ, Ferris CD et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 2000; 97: 4926-4931.
12. Baranano DE, Ferris CD, Snyder SH. Atypical neural messengers. Trends Neurosci 2001; 24: 99-106.
13. Boehning D, Snyder SH. Novel neural modulators. Annu Rev Neurosci 2003; 26: 105-131.
14. Wolosker H, Blackshaw S, Snyder SH. Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Acad Sci USA 1999; 96: 13409-13414.
15. Wolosker H, Sheth KN, Takahashi M, Mothet JP, Brady Jr RO, Ferris CD et al. Purification of serine racemase: biosynthesis of the neuromodulator D-serine. Proc Natl Acad Sci USA 1999; 96: 721-725.
16. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994; 151: 1234-1236.
17. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996; 169: 610-617.
18. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44: 1081-1089.
19. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56: 21-27.
20. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56: 29-36.
21. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 2002; 99: 13675-13680.
22. Hattori E, Liu C, Badner JA, Bonner TI, Christian SL, Maheshwari M et al. Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series. Am J Hum Genet 2003; 72: 1131-1140.
23. Chen YS, Akula N, Detera-Wadleigh SD, Schulze TG, Thomas J, Potash JB et al. Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33. Mol Psychiatry 2004; 9: 87-92; image 85.
24. Schumacher J, Jamra RA, Freudenberg J, Becker T, Ohlraun S, Otte AC et al. Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol Psychiatry 2004; 9: 203-207.
25. Addington AM, Gornick M, Sporn AL, Gogtay N, Greenstein D, Lenane M et al. Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified. Biol Psychiatry 2004; 55: 976-980.
26. Wang X, He G, Gu N, Yang J, Tang J, Chen Q et al. Association of G72/G30 with schizophrenia in the Chinese population. Biochem Biophys Res Commun 2004; 319: 1281-1286.
27. Korostishevsky M, Kaganovich M, Cholostoy A, Ashkenazi M, Ratner Y, Dahary D et al. Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol Psychiatry 2004; 56: 169-176.
28. Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Toyoshima M et al. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol Psychiatry 2005; 57: 1493-1503.
29. Pulver AE, Karayiorgou M, Wolyniec PS, Lasseter VK, Kasch L, Nestadt G et al. Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1: Part 1. Am J Med Genet 1994; 54: 36-43.
30. Pulver AE, Karayiorgou M, Lasseter VK, Wolyniec P, Kasch L, Antonarakis S et al. Follow-up of a report of a potential linkage for schizophrenia on chromosome 22q12-q13.1: Part 2. Am J Med Genet 1994; 54: 44-50.
31. Karayiorgou M, Gogos JA. A turning point in schizophrenia genetics. Neuron 1997; 19: 967-979.
32. Pulver AE. Search for schizophrenia susceptibility genes. Biol Psychiatry 2000; 47: 221-230.
33. Liu H, Abecasis GR, Heath SC, Knowles A, Demars S, Chen YJ et al. Genetic variation in the 22q11 locus and susceptibility to schizophrenia. Proc Natl Acad Sci USA 2002; 99: 16859-16864.
34. Karayiorgou M, Gogos JA. The molecular genetics of the 22q11-associated schizophrenia. Brain Res Mol Brain Res 2004; 132: 95-104.
35. Karayiorgou M, Gogos JA, Galke BL, Wolyniec PS, Nestadt G, Antonarakis SE et al. Identification of sequence variants and analysis of the role of the catechol-O-methyl-transferase gene in schizophrenia susceptibility. Biol Psychiatry 1998; 43: 425-431.
36. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917-6922.
37. Mukai J, Liu H, Burt RA, Swor DE, Lai WS, Karayiorgou M et al. Evidence that the gene encoding ZDHHC8 contributes to the risk of schizophrenia. Nat Genet 2004; 36: 725-731.
38. Gogos JA, Santha M, Takacs Z, Beck KD, Luine V, Lucas LR et al. The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat Genet 1999; 21: 434-439.
39. Liu H, Heath SC, Sobin C, Roos JL, Galke BL, Blundell ML et al. Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci USA 2002; 99: 3717-3722.
40. Jacquet H, Raux G, Thibaut F, Hecketsweiler B, Houy E, Demilly C et al. PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. Hum Mol Genet 2002; 11: 2243-2249.
41. Ozeki Y, Tomoda T, Kleiderlein J, Kamiya A, Bord L, Fujii K et al. Disrupted-in-Schizophrenia-1 (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proc Natl Acad Sci USA 2003; 100: 289-294.
42. Staudinger J, Lu J, Olson EN. Specific interaction of the PDZ domain protein PICK1 with the COOH terminus of protein kinase C-alpha. J Biol Chem 1997; 272: 32019-32024.
43. Banker G, Goslin K (eds). Culturing Nerve Cells, 2nd edn. MIT Press: Cambridge, MA, 1998.
44. Nakata K, Ujike H, Sakai A, Takaki M, Imamura T, Tanaka Y et al. The human dihydropyrimidinase-related protein 2 gene on chromosome 8p21 is associated with paranoid-type schizophrenia. Biol Psychiatry 2003; 53: 571-576.
45. Uchida N, Ujike H, Nakata K, Takaki M, Nomura A, Katsu T et al. No association between the sigma receptor type 1 gene and schizophrenia: results of analysis and meta-analysis of case-control studies. BMC Psychiatry 2003; 3: 13.
46. Hong CJ, Liao DL, Shih HL, Tsai SJ. Association study of PICK1 rs3952 polymorphism and schizophrenia. Neuroreport 2004; 15: 1965-1967.
47. De la Vega FM, Lazaruk KD, Rhodes MD, Wenz MH. Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping System. Mutat Res 2005; 573: 111-135.
48. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
49. Kim PM, Aizawa H, Kim PS, Huang AS, Wickramasinghe SR, Kashani AH et al. Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration. Proc Natl Acad Sci USA 2005; 102: 2105-2110.
50. Staudinger J, Zhou J, Burgess R, Elledge SJ, Olson EN. PICK1: a perinuclear binding protein and substrate for protein kinase C isolated by the yeast two-hybrid system. J Cell Biol 1995; 128: 263-271.
51. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003; 19: 149-150.
52. Chung HJ, Xia J, Scannevin RH, Zhang X, Huganir RL. Phosphorylation of the AMPA receptor subunit GluR2 differentially regulates its interaction with PDZ domain-containing proteins. J Neurosci 2000; 20: 7258-7267.
53. Dev KK, Nishimune A, Henley JM, Nakanishi S. The protein kinase C alpha binding protein PICK1 interacts with short but not long form alternative splice variants of AMPA receptor subunits. Neuropharmacology 1999; 38: 635-644.
54. Xia J, Zhang X, Staudinger J, Huganir RL. Clustering of AMPA receptors by the synaptic PDZ domain-containing protein PICK1. Neuron 1999; 22: 179-187.
55. Boudin H, Doan A, Xia J, Shigemoto R, Huganir RL, Worley P et al. Presynaptic clustering of mGluR7a requires the PICK1 PDZ domain binding site. Neuron 2000; 28: 485-497.
56. Hirbec H, Perestenko O, Nishimune A, Meyer G, Nakanishi S, Henley JM et al. The PDZ proteins PICK1, GRIP, and syntenin bind multiple glutamate receptor subtypes. Analysis of PDZ binding motifs. J Biol Chem 2002; 277: 15221-15224.
57. Dev KK, Nakanishi S, Henley JM. Regulation of mglu(7) receptors by proteins that interact with the intracellular C-terminus. Trends Pharmacol Sci 2001; 22: 355-361.
58. Dev KK, Nakajima Y, Kitano J, Braithwaite SP, Henley JM, Nakanishi S. PICK1 interacts with and regulates PKC phosphorylation of mGLUR7. J Neurosci 2000; 20: 7252-7257.
59. Torres GE, Yao WD, Mohn AR, Quan H, Kim KM, Levey AI et al. Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron 2001; 30: 121-134.
60. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-483.
61. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-719.
62. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1: 179-186.
63. Sawa A, Pletnikov MV, Kamiya A. Neuron-glia interactions clarify genetic-environmental links in mental illness. Trends Neurosci 2004; 27: 294-297.
64. Newman EA. New roles for astrocytes: regulation of synaptic transmission. Trends Neurosci 2003; 26: 536-542.